Previous studies have indicated type I IFN-regulated chemokines (e.g. CXCL10, CCL2 and CCL19) and other chemokines (CXCL8/IL-8) as potential biomarkers for disease activity in SLE (10–15). This evidence concerns the gene CCL19 and systemic lupus erythematosus.